Aggrecan (ACAN) (AA 20-675) (Active) Protein

Details for Product No. ABIN2666766, Supplier: Log in to see
Protein Name
  • AGC1
  • AGCAN
  • CSPG1
  • CSPGCP
  • MSK16
  • SEDK
  • Agc
  • Agc1
  • Cspg1
  • b2b183Clo
  • cmd
  • ARALAR
  • aggrecan
  • solute carrier family 25 (aspartate/glutamate carrier), member 12
  • LOC100380783
  • ACAN
  • Acan
  • AGC
  • SLC25A12
Protein Characteristics
AA 20-675
2
1
1
1
1
1
1
1
1
1
1
1
Origin
Human
11
4
4
1
1
Source
HEK-293
17
2
1
1
Protein Type
Recombinant
Biological Activity
Active
Application
Flow Cytometry (FACS), ELISA
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Purity > 95 % , as determined by Coomassie stained SDS-PAGE.
Sterility 0.22 μm filtered
Endotoxin Level

Less than 0.1 EU per μg of protein as determine by the LAL method.

Background Aggrecan, also known as aggrecan 1, is the major proteoglycan in the articular cartilage. This high molecular weight protein exhibits a bottlebrush structure, in which chondroitin sulfate and keratan sulfate chains are attached to an extended protein core. Aggrecan plays an important role in the proper functioning of articular cartilage by providing a hydrated gel structure through its interaction with hyaluronan and link proteins, that endows the cartilage with load-bearing properties. Aggrecan is expressed by chondrocytes and found to be crucial in chondroskeletal morphogenesis during development. Mutations in this gene may be involved in skeletal dysplasia and spinal degeneration. Structurally, aggrecan is composed of two globular structural domains (G1 and G2) at the N-terminal end and one globular domain (G3) at the C-terminal end, separated by a large extended domain (CS) heavily modified with glycosaminoglycans. G1 and G2 domains of aggrecan are separated by the interglobular domain (IGD). Biologically, the G1 domain interacts with hyaluronan acid and link proteins, forming stable ternary complexes in the extracellular matrix (ECM). The G2 domain is homologous to the tandem repeats of G1 and link proteins, and is involved in product processing. G3 makes up the carboxyl terminus of the core protein, and enhances glycosaminoglycan modification and product secretion. Also, the G3 domain links the proteoglycan aggregates to the ECM proteins (fibulins and tenascins). Degradation of aggrecan appears to initiate at the C-terminus. The population of aggrecan molecules without the G3 domain increases with aging.
Molecular Weight This 672 amino acid recombinant protein with a C-terminal His tag has a predicted molecular mass of approximately 74.3 kDa. The protein migrates at about 120 kDa by SDS-PAGE in DTT-reducing and non-reducing conditions. The predicted N-terminal amino acid
Research Area Stem Cells, Extracellular Matrix
Pathways Glycosaminoglycan Metabolic Process, Dicarboxylic Acid Transport
Application Notes Optimal working dilution should be determined by the investigator.
Comment

Biological activity: Recombinant human aggrecan (G1-IGD-G2) binds immobilized hyaluronan-biotin (0.1 μg/ml) on a streptavidin plate in a dose dependent manner with a ED50 of 2.5 - 9.0 μg/ml.

Restrictions For Research Use only
Format Liquid
Reconstitution For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.
Concentration 200 μg/mL
Buffer 0.22 μm filtered protein solution is in PBS.
Handling Advice Avoid repeated freeze/thaw cycles.
Storage -20 °C
Storage Comment Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.
Supplier Images
Flow Cytometry (FACS) image for Aggrecan (ACAN) (AA 20-675) (Active) Protein (ABIN2666766) Aggrecan (ACAN) (AA 20-675) (Active) protein
Background publications Melin Fürst, Mörgelin, Vadstrup, Heinegård, Aspberg, Blom: "The C-type lectin of the aggrecan G3 domain activates complement." in: PLoS ONE, Vol. 8, Issue 4, pp. e61407, 2013 (PubMed).

Nap, Szleifer: "Structure and interactions of aggrecans: statistical thermodynamic approach." in: Biophysical journal, Vol. 95, Issue 10, pp. 4570-83, 2008 (PubMed).

Roughley, Martens, Rantakokko, Alini, Mwale, Antoniou: "The involvement of aggrecan polymorphism in degeneration of human intervertebral disc and articular cartilage." in: European cells & materials, Vol. 11, pp. 1-7; discussion 7, 2006 (PubMed).

Kiani, Chen, Wu, Yee, Yang: "Structure and function of aggrecan." in: Cell research, Vol. 12, Issue 1, pp. 19-32, 2002 (PubMed).

Doege, Sasaki, Kimura, Yamada: "Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms." in: The Journal of biological chemistry, Vol. 266, Issue 2, pp. 894-902, 1991 (PubMed).